These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32308151)

  • 1. MicroRNAs diagnostic and prognostic value as predictive markers for malignant mesothelioma.
    Sturchio E; Berardinelli MG; Boccia P; Zanellato M; Gioiosa S
    Arch Environ Occup Health; 2020; 75(8):471-482. PubMed ID: 32308151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
    Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
    Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis.
    Micolucci L; Akhtar MM; Olivieri F; Rippo MR; Procopio AD
    Oncotarget; 2016 Sep; 7(36):58606-58637. PubMed ID: 27259231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Possible use of microRNAs as biomarkers for monitoring of workers exposed to asbestos].
    Sturchio E; Amadori A; Businaro J; Ficociello B; Ferrazza P; Colosio C; Minoia C
    G Ital Med Lav Ergon; 2012; 34(3 Suppl):571-3. PubMed ID: 23405719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [microRNAs as biological indicators of environmental and occupational exposure to asbestos].
    Minoia C; Sturchio E; Porro B; Ficociello B; Zambelli A; Imbriani M
    G Ital Med Lav Ergon; 2011; 33(4):420-34. PubMed ID: 22452101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of microRNAs in malignant mesothelioma.
    Truini A; Coco S; Alama A; Genova C; Sini C; Dal Bello MG; Barletta G; Rijavec E; Burrafato G; Boccardo F; Grossi F
    Cell Mol Life Sci; 2014 Aug; 71(15):2865-78. PubMed ID: 24562347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma.
    Santarelli L; Staffolani S; Strafella E; Nocchi L; Manzella N; Grossi P; Bracci M; Pignotti E; Alleva R; Borghi B; Pompili C; Sabbatini A; Rubini C; Zuccatosta L; Bichisecchi E; Valentino M; Horwood K; Comar M; Bovenzi M; Dong LF; Neuzil J; Amati M; Tomasetti M
    Lung Cancer; 2015 Dec; 90(3):457-64. PubMed ID: 26431916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus Report of the 2015 Weinman International Conference on Mesothelioma.
    Carbone M; Kanodia S; Chao A; Miller A; Wali A; Weissman D; Adjei A; Baumann F; Boffetta P; Buck B; de Perrot M; Dogan AU; Gavett S; Gualtieri A; Hassan R; Hesdorffer M; Hirsch FR; Larson D; Mao W; Masten S; Pass HI; Peto J; Pira E; Steele I; Tsao A; Woodard GA; Yang H; Malik S
    J Thorac Oncol; 2016 Aug; 11(8):1246-1262. PubMed ID: 27453164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion.
    Ak G; Tomaszek SC; Kosari F; Metintas M; Jett JR; Metintas S; Yildirim H; Dundar E; Dong J; Aubry MC; Wigle DA; Thomas CF
    Biomed Res Int; 2015; 2015():635748. PubMed ID: 25756049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Artichoke phytocomplex modulates serum microRNAs in patients exposed to asbestos: a first step of a phase II clinical trial.
    Muti P; Sacconi A; Pulito C; Orlandi G; Donzelli S; Morrone A; Jiulian J; Cox GP; Kolb M; Pond G; Kavsak P; Levine MN; Blandino G; Strano S
    J Exp Clin Cancer Res; 2022 Aug; 41(1):255. PubMed ID: 35987988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant mesothelioma in Lynch syndrome: A report of two cases and a review of the literature.
    Shih AR; Kradin RL
    Am J Ind Med; 2019 May; 62(5):448-452. PubMed ID: 31033031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
    Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
    J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.
    Weber DG; Gawrych K; Casjens S; Brik A; Lehnert M; Taeger D; Pesch B; Kollmeier J; Bauer TT; Johnen G; Brüning T
    Dis Markers; 2017; 2017():9280170. PubMed ID: 28321148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity of mesothelin in occupational medicine practice.
    Smolková P; Nakládalová M; Zapletalová J; Jakubec P; Vildová H; Kolek V; Petřek M; Nakládal Z
    Int J Occup Med Environ Health; 2016; 29(3):395-404. PubMed ID: 26988879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asbestos-related lung cancer and malignant mesothelioma of the pleura: selected current issues.
    Markowitz S
    Semin Respir Crit Care Med; 2015 Jun; 36(3):334-46. PubMed ID: 26024342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Five years update on relationships between malignant pleural mesothelioma and exposure to asbestos and other elongated mineral particles.
    Andujar P; Lacourt A; Brochard P; Pairon JC; Jaurand MC; Jean D
    J Toxicol Environ Health B Crit Rev; 2016; 19(5-6):151-172. PubMed ID: 27705546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secreted and Tissue miRNAs as Diagnosis Biomarkers of Malignant Pleural Mesothelioma.
    Martínez-Rivera V; Negrete-García MC; Ávila-Moreno F; Ortiz-Quintero B
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
    Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
    PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genetic variant of NLRP1 gene is associated with asbestos body burden in patients with malignant pleural mesothelioma.
    Crovella S; Moura RR; Cappellani S; Celsi F; Trevisan E; Schneider M; Brollo A; Nicastro EM; Vita F; Finotto L; Zabucchi G; Borelli V
    J Toxicol Environ Health A; 2018; 81(5):98-105. PubMed ID: 29265930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
    Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
    Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.